Stockscreener 앱 받기
1.20
5.26%
0.06
시간 외 거래:
1.20
전일 마감가:
$1.14
열려 있는:
$1.1805
하루 거래량:
2,447
Relative Volume:
0.05
시가총액:
$13.89M
수익:
$996.00K
순이익/손실:
$-6.09M
주가수익비율:
-2.2642
EPS:
-0.53
순현금흐름:
$-9.76M
1주 성능:
+4.35%
1개월 성능:
+8.11%
6개월 성능:
+11.11%
1년 성능:
-32.96%
1일 변동 폭
$1.1805
$1.20
1주일 범위
$1.1192
$1.20
52주 변동 폭
$0.70
$2.44
Therapeuticsmd Inc Stock (TXMD) Company Profile
명칭
Therapeuticsmd Inc
전화
561-961-1900
주소
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
TXMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.20 | 13.19M | 996.00K | -6.09M | -9.76M | -0.53 |
|
ZTS
Zoetis Inc
|
153.45 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.75 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.58 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.61 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-08-07 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2020-05-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-12-02 | 개시 | Guggenheim | Buy |
| 2019-10-17 | 개시 | H.C. Wainwright | Buy |
| 2019-04-30 | 재개 | Noble Capital Markets | Outperform |
| 2018-06-15 | 개시 | JP Morgan | Overweight |
| 2017-09-08 | 개시 | Morgan Stanley | Equal-Weight |
| 2017-07-11 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2017-05-09 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2016-11-22 | 재개 | Jefferies | Buy |
| 2016-11-22 | 개시 | Oppenheimer | Outperform |
| 2016-11-07 | 재개 | Guggenheim | Buy |
| 2016-04-04 | 개시 | Goldman | Buy |
| 2015-12-08 | 재확인 | Jefferies | Buy |
| 2015-12-08 | 재확인 | Stifel | Buy |
| 2015-09-21 | 재확인 | Jefferies | Buy |
| 2015-06-09 | 개시 | Guggenheim | Buy |
| 2014-07-08 | 개시 | FBR Capital | Outperform |
| 2014-04-17 | 재확인 | Noble Financial | Buy |
| 2014-01-28 | 재확인 | Noble Financial | Buy |
모두보기
Therapeuticsmd Inc 주식(TXMD)의 최신 뉴스
Is TherapeuticsMD Inc. a good long term investmentExceptional trading performance - Autocar Professional
TherapeuticsMD Inc. Stock Analysis and ForecastHigh-octane investment gains - Autocar Professional
What drives TherapeuticsMD Inc. stock priceFree Consultation - Autocar Professional
What analysts say about TherapeuticsMD Inc. stockHigh-yield capital appreciation - Autocar Professional
How TherapeuticsMD Inc. stock performs during market volatilityFree Stock Market Analysis Courses - Newser
TherapeuticsMD (NASDAQ:TXMD) Shares Down 0.8% – What’s Next? - Defense World
What makes TherapeuticsMD Inc. stock price move sharplyIntraday Trade Ideas - Newser
Why TherapeuticsMD Inc. stock attracts strong analyst attentionMinimized Risk Maximum Return - Newser
Mayne Pharma Group Unit Seeks Over $11.5 Million in Damages in US Court Complaint Against TherapeuticsMD - marketscreener.com
Mayne Pharma Files Legal Complaint Against TherapeuticsMD - TipRanks
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com - Defense World
TherapeuticsMD Reports Improved Q1 2025 Results - TipRanks
TherapeuticsMD Announces First Quarter 2025 Financial Results | - GuruFocus
TherapeuticsMD: Q1 Earnings Snapshot - CT Insider
TherapeuticsMD Announces First Quarter 2025 Financial Results - BioSpace
TherapeuticsMD Inc Reports Q1 2025 Results: EPS at -$0.06, Revenue Reaches $393K - GuruFocus
TherapeuticsMD Reports Q1 2025 Financial Results - TipRanks
TherapeuticsMD Q1 Operating Expenses USD 1.264 Million - marketscreener.com
TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com - Defense World
Today's Dead Cat Bounce Stock: TherapeuticsMD (TXMD) - TheStreet
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
Press Release Distribution & PR Platform - ACCESS Newswire
Therapeuticsmd Inc (TXMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.34%
자본화:
|
볼륨(24시간):